Jun 18, 2025 09:00AM CEL-SCI Corp (CVM): FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway

May 22, 2025 05:44AM CEL-SCI Corp (CVM) Offering 2M Shares at $2.50

May 21, 2025 04:13PM CEL-SCI Corp (CVM) Announces Proposed Public Offering

May 21, 2025 08:08AM CEL-SCI Corp's (CVM) Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

May 19, 2025 02:40PM CEL-SCI Corp (CVM) approves 1 for 30 combination of common stock

May 15, 2025 05:13PM CEL-SCI Corp (CVM) Reports Q2 Loss of $0.08

Apr 23, 2025 08:31AM CEL-SCI Corp (CVM) to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

Mar 17, 2025 03:24PM CEL-SCI Corp (CVM) Prices 16M Share Offering

Mar 17, 2025 08:02AM CEL-SCI Corp's (CVM) Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Feb 20, 2025 08:06AM CEL-SCI Corp (CVM) to Initiate Multikine Confirmatory Phase 3 Cancer Trial

Dec 31, 2024 04:05PM CEL-SCI Corp (CVM) Closes $5M Offering

Dec 30, 2024 06:47AM CEL-SCI Corp (CVM) Prices 16.13M Share Offering at $0.31/sh

Dec 27, 2024 05:12PM CEL-SCI Corp (CVM) Announces Proposed Share Offering

Nov 7, 2024 08:16AM U.S. FDA and CEL-SCI (CVM) Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Oct 25, 2024 05:20PM CEL-SCI Corp (CVM) Files for 1M Share Offering by Selling Stockholders

Oct 22, 2024 09:15AM CEL-SCI Corp (CVM): FDA’s ODAC Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Oct 8, 2024 05:16PM CEL-SCI Corp (CVM) Files $150M Mixed Shelf

Sep 16, 2024 07:33AM CEL-SCI Corp's (CVM) Multikine Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

Sep 13, 2024 03:25PM CEL-SCI Corp (CVM) September 1 calls active as share price up 6.6%

Sep 4, 2024 09:03AM CEL-SCI Corp (CVM): UK’s Medicines & Healthcare Products Regulatory Agency Grants Pediatric Waiver, Bringing Multikine One Step Closer to Future Marketing Clearance

Aug 15, 2024 08:32AM CEL-SCI Corp (CVM) Misses Q3 EPS by 42c

Jul 26, 2024 11:53AM CEL-SCI Corp (CVM) Prices $10.8 Million Offering

Jul 26, 2024 10:47AM CEL-SCI Corp (CVM) Halted, News Pending

Jul 26, 2024 08:26AM CEL-SCI Corp (CVM) Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results